Clinical trials: Esophageal Cancer Metastatic
Resectable Esophageal Cancer
Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer
Despite the availability of several preoperative diagnostic techniques, accurate pretreatment staging of esophageal cancer (EC) remains challenging.
- Trial name
- NCT01858805
- Testing
- esophagectomy
- Where
- Germany
- Volunteers
- 123 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Esophageal Squamous Cell Carcinoma
KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.
- Trial name
- NCT03927495
- Testing
- KN046, palliative radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Neoplasms
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently.
- Trial name
- NCT06086457
- Testing
- Radiation, TP or PF regimen depended on investigator's choice., PD-1 inhibitor
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT00539617
- Testing
- Erlotinib, 5-fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
RATIONALE: Everolimus may stop the growth of stomach or esophageal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01231399
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Gastric Cancer, Esophageal Cancer
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
The INTEGA study assesses therapy Options for advanced or metastatic esophagogastric Adenocarcinoma in patients overexpressing human epidermal receptor type 2 (HER2 positive patients).
- Conditions
- Gastric Cancer, Esophageal Cancer, Adenocarcinoma Gastric, HER2 Positive Gastric Cancer
- Trial name
- INTEGA (NCT03409848)
- Testing
- Nivolumab, Ipilimumab
- Where
- 35 sites in Germany
- Volunteers
- 97 people
- Sponsor
- AIO-Studien-gGmbH
Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07583316
- Testing
- CRPA1A2
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Metastatic Esophageal Cancer, Metastatic Gastric Cancer
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with advanced unresectable or metastatic OGA who…
- Trial name
- NCT04166721
- Testing
- Atezolizumab
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Gastric Adenocarcinoma, Barrett Esophagus
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
This trial will be conducted to evaluate the efficacy, safety, and tolerability of sunitinib (sunitinib-malate) as a second-line palliative therapy in metastatic gastric cancer.
- Trial name
- NCT00411151
- Testing
- Sunitinib-Malate
- Where
- 12 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Johannes Gutenberg University Mainz
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Gastric Cancer, Esophageal Cancer
Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer
GASTROBRAIN trial is an international (2 countries) observational, multicenter (15 centers) retrospective cohort study designed to investigate local treatment strategies for brain metastases of gastric and esophageal cancer
- Conditions
- Gastric Cancer, Esophageal Cancer, Brain Metastases
- Trial name
- GASTROBRAIN (NCT07448493)
- Testing
- Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR), Radiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT), Combined Local Treatment Modalities
- Where
- 15 sites in Belarus, Russia
- Volunteers
- 230 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Esophageal Cancer, Gastric Cancer
DX-8951f in Treating Patients With Metastatic Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00017212
- Testing
- exatecan mesylate
- Where
- 6 sites in United States, Canada
- Sponsor
- Daiichi Sankyo
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is one of the malignant tumors with a high incidence worldwide, especially remaining persistently high in Asian regions.
- Trial name
- NCT07142421
- Testing
- Combination therapy (COMB)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Gastric Cancer, Colon Cancer
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer
- Trial name
- NCT06126406
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
This phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it…
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm
- Trial name
- NCT07594626
- Testing
- Biospecimen Collection, Computed Tomography, Pemetrexed
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Northwestern University
Esophageal Cancer
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00109850
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- 132 sites in United States
- Volunteers
- 22 people
- Sponsor
- SWOG Cancer Research Network
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)